Therapeutics

Experts weigh pros and cons of treatment option for orbital cellulitis in pediatric patients

Experts in the field weigh in on the perfluorohexyloctane ophthalmic solution, the first and only FDA-approved treatment for DED that directly targets tear evaporation instead of tear formation.

AG-80208 is a novel, first-in-class, formyl peptide receptor (FPR) agonist formulated as an aqueous solution eye drop to treat the inflammation linked with DED.

In April, the FDA approved an update to the TEPEZZA indication language, specifying its use in all patients with TED regardless of TED activity or duration. Horizon Therapeutics presented its data at the Endocrine Society's 2023 annual meeting in Chicago.

The clinical trial successfully achieved statistical significance for the primary endpoint and all secondary endpoints.

On this episode of the NeuroOp Guru video blog, Andy Lee, MD, and Drew Carey, MD, discuss the use of fluoxetine in patients with visual field loss after suffering a stroke.

The MERIT study found that intraocular corticosteroid treatment remains the most effective therapy for uveitis-related macular edema, and vision gains in participants who received the corticosteroid treatment were very promising.

According to the company, topline results from the clinical trial are expected by the third quarter of 2024.

Treatment option offers positive outcome for patients diagnosed with disease.

Therapeutic has fewer adverse effects in patients with POAG, OHT.

New option a potential treatment for patients diagnosed with dry eye disease.

While the 6-weekly regimen was less effective in improving the clinical activity score or exophthalmos than the higher dose regimen, it is an acceptable treatment choice for patients with marginal or lower clinical activity scores.

The lawsuit states the $27.8 billion acquisition would allow Amgen to strengthen their drug portfolio and stifle drug competition in a bid to monopolize two fast-growing medications.

The company noted YUTIQ is used for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and is the same as Alimera’s ILUVIEN.

The goal of the project is to encourage patients with Demodex blepharitis to visit an ophthalmologist.

According to researchers, these chronic, progressive retinal diseases, including retinitis pigmentosa, arise from genetic and environmental disruptions of cellular and tissue stability.

According to the company, the announcement represents the first FDA-approved, fixed-combination of tropicamide and phenylephrine for mydriasis.

Lowe is the VP, of Commercial Operations at Eyenovia, and discussed the FDA approval of MydCombi for mydriasis at the 2023 ASCRS annual meeting in San Diego.

Jim Mazzo, executive chairman of Neurotech Pharmaceuticals, discussed the company's goal to slow down the progression of MacTel and their recent advancements at the ASCRS annual meeting in San Diego.

The study, titled “A Clinical Registry Study of Glaucoma Medication Use in Patients with Mild Glaucoma Severity After MIGS,” will be presented Sunday by Michael Mbagwu, MD, at the American Society of Cataract and Refractive Surgery annual meeting in San Diego, California.

Ophthalmology Times® spoke with Mitch Shultz, MD at ASCRS 2023 in San Diego about the a new FDA clinical trial for a device called StableVisc being launched on the market by Bausch + Lomb.

Jason Bacharach, MD, presented results at the American Society of Cataract and Refractive Surgery annual meeting in San Diego, highlighting that a large phase 3 clinical trial demonstrated no relevant differences between the 2 formulations.

In a presentation at the American Society for Cataract and Refractive Surgery annual meeting in San Diego, Ana Balbuena-Pareja, MSc, explained how cenegermin-bkbj ophthalmic solution 0.002% (Oxervate, Dompé) had a positive effect on corneal nerve regeneration and sensation in patients with neurotrophic keratitis.

APP13007 is used for the treatment of post-operative inflammation and pain following ocular surgery.

Horizon recently received an updated indication for TEPEZZA to specify its use in patients with TED, regardless of disease activity or duration, coming after the company released positive topline results from the phase four clinical trial of patients with chronic TED.